2022 American Transplant Congress
Cmv-Specific Cell-Mediated Immune Reconstitution in High-Risk Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis
*Purpose: In the absence of antiviral prophylaxis following Hematopoietic Cell Transplant (HCT), the incidence of clinically significant cytomegalovirus reactivation (cCMV) is 30% in CMV seropositive…2022 American Transplant Congress
Evaluation of Prophylactic Valganciclovir Dosing in Kidney Transplant Recipients at an Urban Transplant Institution
*Purpose: Dosing and duration of cytomegalovirus (CMV) prophylaxis with valganciclovir (VGC) in kidney transplant (KT) recipients is variable by transplant center. Prior studies have shown…2022 American Transplant Congress
Incidence of Urinary Tract Infection or Asymptomatic Bacteriuria in Kidney Transplant Recipients with Sulfamethoxazole-Trimethoprim vs. Pentamidine for Pneumocystis Jiroveci Pneumonia Prophylaxis
University Health, San Antonio, TX
*Purpose: To compare the incidence of urinary tract infection (UTI) or asymptomatic bacteriuria (ASB) post-kidney transplant (KT) with multiple Pneumocystis jiroveci pneumonia (PJP) prophylaxis regimens*Methods:…2022 American Transplant Congress
Does a Second Transplant Increase the Risk for CMV Infection? An Evaluation of the Incidence of CMV Viremia in the Previously Transplanted Kidney Recipient
*Purpose: Cytomegalovirus (CMV) viremia is a common complication of kidney transplant recipients (KTR) with significant morbidity/mortality. Patients who receive multiple transplants are potentially at a…2022 American Transplant Congress
Preemptive Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting
*Purpose: Preemptive therapy (PET) has demonstrated superiority to antiviral prophylaxis for prevention of cytomegalovirus (CMV) disease in CMV donor seropositive/recipient seronegative (D+R-) liver transplant recipients …2022 American Transplant Congress
Comparison of Cephalexin and Ciprofloxacin Prophylaxis for Urinary Tract Infection in Kidney Transplant Recipients
Transplant Institute, Henry Ford Hospital, Detroit, MI
*Purpose: Compare efficacy and safety outcomes of patients (pts) that received alternative agents as prophylaxis (ppx) for urinary tract infection (UTI) after kidney transplant (KT)…2022 American Transplant Congress
Early versus Delayed Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
1Pharmacy, Houston Methodist Hospital, Houston, TX, 2Pharmacy, Nebraska Medicine, Omaha, NE
*Purpose: The purpose of this study is to determine the effect of delaying cytomegalovirus (CMV) prophylaxis to day of discharge or post-operative day (POD) 7…2021 American Transplant Congress
Perioperative Anidulafungin Combined with Triazole Prophylaxis for the Prevention of Early Invasive Candidiasis in Lung Transplant Recipients
*Purpose: Invasive candidiasis (IC) is a substantial cause of morbidity and mortality in lung transplant recipients (LTRs). Post-operative factors, such as prolonged hospital stay, central…2021 American Transplant Congress
Methenamine for the Prevention of Recurrent UTIs Post-Renal Transplant
*Purpose: Urinary tract infections (UTIs) are a highly prevalent postoperative complication in kidney transplant recipients (KTRs), occurring in approximately 34% of patients. The common method…2021 American Transplant Congress
Outcomes Among CMV Mismatched and Highly Sensitized Kidney Transplant Recipients Who Develop Leukopenia or Neutropenia
*Purpose: Kidney transplant recipients (KTRs) who receive antiproliferative agents for immunosuppression and valganciclovir for CMV prophylaxis are at high risk of developing leukopenia and neutropenia.…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »